ChromaDex, Inc.
10005 Muirlands Boulevard
Suite G, First Floor
Irvine
California
92618
United States
Tel: 949-419-0288
Fax: 949-419-0294
Website: http://www.chromadex.com/
Email: custsvc@chromadex.com
247 articles about ChromaDex, Inc.
-
ChromaDex, Inc. Opens New State-of-the-Art Research And Development Center In Longmont
1/5/2017
-
California Biotech ChromaDex, Inc. to Set Up New R&D Plant in Longmont
12/27/2016
-
ChromaDex, Inc. Release: U.S. FDA Issues GRAS No Objection Letter For NIAGEN
8/16/2016
-
ChromaDex, Inc. Vindicated By Retraction And Apology From Author Of Misleading And Factually Inaccurate Article
6/30/2016
-
ChromaDex, Inc. Added To The Russell 2000 Index
6/28/2016
-
ChromaDex, Inc. Release: University Researchers Show Vitamin Nicotinamide Riboside Is An Effective Tool For Managing The Negative Effects Of Obesity And Diabetes
6/1/2016
-
ChromaDex, Inc. Announces Reverse Stock Split As Company Seeks To List Its Common Stock On The NASDAQ Capital Market
4/13/2016
-
ChromaDex, Inc. Announces Commencement Of An Obesity-Related Clinical Study Of NIAGEN In Collaboration With The University of Copenhagen And Aarhus University
2/22/2016
-
A Letter From the ChromaDex, Inc. Chief Executive Officer
1/6/2016
-
ChromaDex, Inc. To Present At 27th Annual Piper Jaffray Healthcare Conference
11/24/2015
-
Jarrow Formulas Plans U.S. Retail Launch Of A Nicotinamide Riboside Product Featuring ChromaDex, Inc.’s NIAGEN
11/23/2015
-
NIH And ChromaDex, Inc. Announce Material Cooperative Research And Development Agreement To Study The Effects Of Chromadex’s NIAGEN Nicotinamide Riboside On Cockayne Syndrome And Ataxia Telangiectasia
11/18/2015
-
ChromaDex, Inc. Lead Ingredient NIAGEN Nicotinamide Riboside Receives New Dietary Ingredient (NDI) Status From The FDA
11/16/2015
-
ChromaDex, Inc. Enters Into An Exclusive Joint Development Agreement With The Procter & Gamble
11/5/2015
-
ChromaDex, Inc. Announces $2,000,000 Registered Direct Offering
11/5/2015
-
ChromaDex, Inc. Presentation Now Available For On-Demand Viewing
10/8/2015
-
ChromaDex, Inc. To Webcast, Live, At VirtualInvestorConferences.com October 1
9/28/2015
-
Results From First Human Clinical Study Demonstrate ChromaDex, Inc.'s NIAGEN Nicotinamide Riboside Effectively Increases The Co-Enzyme NAD+ And Is Safe
8/12/2015
-
ChromaDex, Inc. Announces A Collaborative Human Clinical Study On NIAGEN With The University of Colorado Boulder
6/18/2015
-
ChromaDex, Inc. To Present At The LD Micro Invitational Conference On June 2, 2015
5/20/2015